References
- International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
- da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population-based cohort. Blood. 2016;128(17):2181–2183.
- Mato A, Nabhan C, Kay NE, et al. Real-world clinical experience in the Connect. Br J Haematol. 2016;175(5):892–903.
- Mato A, Nabhan C, Kay NE, et al. Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization/cytogenetics: a real-world clinical experience in the connect CLL registry. Clin Lymphoma Myeloma Leuk. 2018;18(2):114–124.e2.
- Mato AR, Barrientos JC, Brander D, et al. Prognostic testing and treatment approaches based on real-world clinical experience from an interim analysis of the informcll registry of patients with chronic lymphocytic leukemia: pf383. HemaSphere. 2019;3:143–144.
- Delgado J, Baumann T, Mozas P, et al. CLL: is lymphocyte doubling time (LDT) a relevant prognostic parameter in the era of prognostic biomarkers? EHA Library. 2017;180807:E1031.
- Rozovski U, Keating MJ, Estrov Z. Why is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia? Acta Haematol. 2018;140(1):51–54.
- Hallek M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018;131(25):2745–2760.
- Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–4685.
- Wierda WG, O’Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011;29(31):4088–4095.
- Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62.
- Gentile M, Shanafelt TD, Cutrona G, et al. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia. 2016;30(6):1440–1443.
- Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127(14):1752–1760.
- Montserrat E, Sanchez-Bisono J, Viñolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62(3):567–575.